The preclinical study also reported an upregulation of the cannabinoid receptor type 2 transcript CB2A in the animal model of autism [25], which was discussed by the authors themselves to contrast it with diametral evidence provided by the same research group for lower CB2 receptor function in schizophrenia [63]. The gene discussed is CNR2; the disease is schizophrenia.